48 R.G. Pertwee
Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
Life Sci 76:1307–1324
PertweeRG,RossRA(2002)Cannabinoidreceptorsandtheirligands.ProstaglandinsLeukot
Essent Fatty Acids 66:101–121
Pertwee RG, Coutts AA, Griffin G, Fernando SR, McCallion D, Stevenson L (1996a) Pres-
ence of cannabinoid CB1 receptors on prejunctional neurones of certain isolated tissue
preparations: a brief review. Med Sci Monit 2:840–848
Pertwee RG, Fernando SR, Griffin G, Ryan W, Razdan RK, Compton DR, Martin BR (1996b)
Agonist-antagonist characterization of 6’-cyanohex-2’-yne-∆8-tetrahydrocannabinol in
two isolated tissue preparations. Eur J Pharmacol 315:195–201
Pertwee RG, Gibson TM, Stevenson LA, Ross RA, Banner WK, Saha B, Razdan RK, Martin BR
(2000)O-1057,apotentwater-solublecannabinoidreceptoragonistwithantinociceptive
properties. Br J Pharmacol 129:1577–1584
Pertwee RG, Ross RA, Craib SJ, Thomas A (2002) (–)-Cannabidiol antagonizes cannabinoid
receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456:99–
106
Petitet F, Marin L, Doble A (1996) Biochemical and pharmacological characterization of
cannabinoid binding sites using [3H]SR141716A. Neuroreport 7:789–792
Petitet F, Jeantaud B, Capet M, Doble A (1997) Interaction of brain cannabinoid recep-
tors with guanine nucleotide binding protein. A radioligand binding study. Biochem
Pharmacol 54:1267–1270
Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998) Complex pharmacology
of natural cannabinoids: evidence for partial agonist activity of∆9-tetrahydrocanna-
binol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci
63:PL1–PL6
Platt B, Drysdale AJ (2004) Search and rescue: identification of cannabinoid actions relevant
for neuronal survival and protection. Curr Neuropharmacol 2:103–114
Porter AC, Sauer J-M, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter
P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabi-
noid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther
301:1020–1024
Portier M, Rinaldi-Carmona M, Pecceu F, Combes T, Poinot-Chazel C, Calandra B, Barth
F, Le Fur G, Casellas P (1999) SR 144528, an antagonist for the peripheral cannabinoid
receptor that behaves as an inverse agonist. J Pharmacol Exp Ther 288:582–589
Rhee M-H, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L, Breuer A, Mechoulam R (1997)
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylyl
cyclase. J Med Chem 40:3228–3233
Richardson JD, Kilo S, Hargreaves KM (1998) Cannabinoids reduce hyperalgesia and in-
flammation via interaction with peripheral CB1 receptors. Pain 75:111–119
Rinaldi-CarmonaM,BarthF,HéaulmeM,ShireD,CalandraB,CongyC,MartinezS,Maruani
J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le Fur G (1994) SR141716A, a potent
and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240–244
Rinaldi-Carmona M, Calandra B, Shire D, Bouaboula M, Oustric D, Barth F, Casellas P,
Ferrara P, Le Fur G (1996a) Characterization of two cloned human CB1 cannabinoid
receptor isoforms. J Pharmacol Exp Ther 278:871–878
Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Barth F, Bachy A, Brelière J-C, Soubrié P, Le
Fur G (1996b) Characterization and distribution of binding sites for [3H]-SR141716A,
a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci
58:1239–1247
Rinaldi-Carmona M, Barth F, Millan J, Derocq J-M, Casellas P, Congy C, Oustric D, Sarran
M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière J-C, Le Fur G (1998) SR 144528,
the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol
Exp Ther 284:644–650
Ross RA (2003) Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 140:790–801